Focused On-demand Library for Peroxisomal leader peptide-processing protease

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q2T9J0

UPID:

TYSD1_HUMAN

Alternative names:

Trypsin domain-containing protein 1

Alternative UPACC:

Q2T9J0; Q5SQT4; Q5SQU1; Q8N6H2; Q96AR5

Background:

The Peroxisomal leader peptide-processing protease, also known as Trypsin domain-containing protein 1, plays a crucial role in peroxisomal function. It is responsible for the cleavage of leader peptides from proteins harboring a PTS2 target sequence and processes several PTS1-containing proteins. This protease is pivotal in the peroxisomal beta-oxidation of fatty acids, a metabolic pathway essential for energy production and lipid metabolism.

Therapeutic significance:

Understanding the role of Peroxisomal leader peptide-processing protease could open doors to potential therapeutic strategies. Its involvement in the critical process of peroxisomal beta-oxidation positions it as a key target for interventions in metabolic disorders.